The acquisition gives GlaxoSmithKline marketing rights to Lovaza in the US and Puerto Rico. In addition to Lovaza, three other cardiovascular products marketed by Reliant – DynaCirc CR (isradipine) and InnoPran XL (propanolol HCl), which treat high blood pressure, and Rythmol SR (propafenone), which treats abnormal heart rhythms, or arrhythmia – will join the GSK portfolio in the US.
GSK expects the transaction will be slightly accretive to earnings in 2008, excluding integration costs, and will create additional value in following years.
Chris Viehbacher, president, US Pharmaceuticals, GSK, said: “We’re eager to begin building on Reliant’s success with Lovaza.”